165 related articles for article (PubMed ID: 19783899)
1. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
[TBL] [Abstract][Full Text] [Related]
2. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
[TBL] [Abstract][Full Text] [Related]
3. Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.
Chang KH; Kim MS; Hong GW; Shin YN; Kim SH
Exp Mol Med; 2012 Jan; 44(1):52-9. PubMed ID: 22064379
[TBL] [Abstract][Full Text] [Related]
4. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide.
Entzminger KC; Hyun JM; Pantazes RJ; Patterson-Orazem AC; Qerqez AN; Frye ZP; Hughes RA; Ellington AD; Lieberman RL; Maranas CD; Maynard JA
Sci Rep; 2017 Aug; 7(1):10295. PubMed ID: 28860479
[TBL] [Abstract][Full Text] [Related]
5. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
[TBL] [Abstract][Full Text] [Related]
6. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
7. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
[TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.
Kelton C; Wesolowski JS; Soloviev M; Schweickhardt R; Fischer D; Kurosawa E; McKenna SD; Gross AW
Arch Biochem Biophys; 2012 Oct; 526(2):219-25. PubMed ID: 22426455
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
Li S; Kussie P; Ferguson KM
Structure; 2008 Feb; 16(2):216-27. PubMed ID: 18275813
[TBL] [Abstract][Full Text] [Related]
10. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
[TBL] [Abstract][Full Text] [Related]
11. Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy.
Wang W; He W; Wang L; Zhang G; Gao B
Immunol Cell Biol; 2013 May; 91(5):360-7. PubMed ID: 23567896
[TBL] [Abstract][Full Text] [Related]
12. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
[TBL] [Abstract][Full Text] [Related]
13. Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.
Khantasup K; Chantima W; Sangma C; Poomputsa K; Dharakul T
Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):404-17. PubMed ID: 26683180
[TBL] [Abstract][Full Text] [Related]
14. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
15. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor.
Alvarenga ML; Kikhney J; Hannewald J; Metzger AU; Steffens KJ; Bomke J; Krah A; Wegener A
Anal Biochem; 2012 Feb; 421(1):138-51. PubMed ID: 22085444
[TBL] [Abstract][Full Text] [Related]
16. SNAP-Tag Technology: A Useful Tool To Determine Affinity Constants and Other Functional Parameters of Novel Antibody Fragments.
Niesen J; Sack M; Seidel M; Fendel R; Barth S; Fischer R; Stein C
Bioconjug Chem; 2016 Aug; 27(8):1931-41. PubMed ID: 27391930
[TBL] [Abstract][Full Text] [Related]
17. Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity.
Chang L; Zhou C; Xu M; Liu J
J Comput Aided Mol Des; 2010 Jan; 24(1):37-47. PubMed ID: 20012671
[TBL] [Abstract][Full Text] [Related]
18. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
[TBL] [Abstract][Full Text] [Related]
19. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.
Koefoed K; Steinaa L; Søderberg JN; Kjær I; Jacobsen HJ; Meijer PJ; Haurum JS; Jensen A; Kragh M; Andersen PS; Pedersen MW
MAbs; 2011; 3(6):584-95. PubMed ID: 22123060
[TBL] [Abstract][Full Text] [Related]
20. A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).
Tu C; Terraube V; Tam AS; Stochaj W; Fennell BJ; Lin L; Stahl M; LaVallie ER; Somers W; Finlay WJ; Mosyak L; Bard J; Cunningham O
J Biol Chem; 2016 Jan; 291(3):1267-76. PubMed ID: 26515064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
